RCM
CSTL icon

Raleigh Capital Management’s Castle Biosciences CSTL Stock Holding History

Raleigh Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-185
Closed -$4.2K – 859
2023
Q1 		$4.2K Buy
185
+25
+16% +$611 ﹤0.01% 641
2022
Q4 		$3.77K Buy
+160
New +$3.71K ﹤0.01% 591

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raleigh Capital Management's CSTL Position: Q2 2023 in Review

Raleigh Capital Management sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 185 shares — an estimated $4.2K sold.

Raleigh Capital Management first reported a position in CSTL in Q4 2022 and held it in 2 quarters. The position peaked at $4.2K in Q1 2023. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Raleigh Capital Management reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Raleigh Capital Management sold 185 Castle Biosciences shares in Q2 2023, an estimated $4.2K.
  • Raleigh Capital Management first reported a position in Castle Biosciences in Q4 2022 and held it in 2 quarters.
  • Raleigh Capital Management's Castle Biosciences position peaked at $4.2K in Q1 2023.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Raleigh Capital Management's 13F filing for Q2 2023, filed 25 Jul 2023.